FGF-21 was report to enhance skeletal muscle glucose uptake [61] and protect lipid disruption and nonalcoholic steatohepatitis [60, 62], even in a clinical trial [63]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.